COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.9 CAD -2.03% Market Closed
Market Cap: 9.4m CAD

COSCIENS Biopharma Inc
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

COSCIENS Biopharma Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
Depreciation & Amortization
$1.3m
CAGR 3-Years
110%
CAGR 5-Years
39%
CAGR 10-Years
18%
Theratechnologies Inc
TSX:TH
Depreciation & Amortization
$1.9m
CAGR 3-Years
-49%
CAGR 5-Years
-25%
CAGR 10-Years
2%
Repare Therapeutics Inc
NASDAQ:RPTX
Depreciation & Amortization
$2.7m
CAGR 3-Years
13%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Depreciation & Amortization
$19.4m
CAGR 3-Years
94%
CAGR 5-Years
70%
CAGR 10-Years
28%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Depreciation & Amortization
$2.6m
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
10%
Spectral Medical Inc
TSX:EDT
Depreciation & Amortization
CA$247k
CAGR 3-Years
-4%
CAGR 5-Years
-3%
CAGR 10-Years
4%
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
7.08 CAD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is COSCIENS Biopharma Inc's Depreciation & Amortization?
Depreciation & Amortization
1.3m USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's Depreciation & Amortization amounts to 1.3m USD.

What is COSCIENS Biopharma Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
18%

Over the last year, the Depreciation & Amortization growth was 3%. The average annual Depreciation & Amortization growth rates for COSCIENS Biopharma Inc have been 110% over the past three years , 39% over the past five years , and 18% over the past ten years .

Back to Top